Latest News

Results of a study performed at the University of Pittsburgh Medical Center (UPMC) reports that high concentrations of specific proteins in the blood of patients with idiopathic pulmonary fibrosis (IPF) that also met specific clinical parameters predicted poor overall survival.

NIH stops one treatment arm of trial; other two treatments to continue

CHICAGO, October 17, 2011 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) announced today that it has established the PFF Research Fund to Cure Pulmonary Fibrosis, a fund created to support research that will assist in the development of successful therapies for pulmonary fibrosis (PF). PF is a progressive and ultimately fatal lung disease that affects more than 200,000 Americans, and takes an estimated 40,000 lives each year. The primary goal of the Fund is to help identify new treatments, and ultimately a cure for PF

Study points to a phosphorylation pathway that may contribute to the development of lung injury and fibrosis

By Dr. Daniel Dilling, FCCP

Lung transplantation, at one time, seemed like science fiction, but innovations in surgical technique and immunosuppression made it clinical reality. Limited supply of donor lungs and the vagaries of immunosuppression still limit its success.

When Mari Foster, RRT, lost one of her patients to pulmonary fibrosis earlier this year, she asked the family about donating money to the church for her mass. The family had another idea: Could Foster help them find out how they could help raise money for the Pulmonary Fibrosis Foundation (PFF) instead?

Oyster Bay, N.Y. – Dr. Yang Zhou, associate research scientist working in Dr. Jack Elias’s lab at the Yale University School of Medicine, has been awarded a grant to investigate potential biomarkers and therapeutic targets of pulmonary fibrosis.